Abstract:The cascade of amyloid formation relates to multiple complex events at the molecular level. Previous research has established amyloid plaque deposition as the leading cause of Alzheimer's disease (AD) pathogenesis, detected mainly in aged population. The primary components of the plaques are two alloforms of amyloid-beta (Aβ), Aβ1-42 and Aβ1-40 peptides. Recent studies have provided considerable evidence contrary to the previous claim indicating that amyloid-beta oligomers (AβOs) as the main culprit responsible for AD-associated neurotoxicity and pathogenesis. In this review, we have discussed the primary features of AβOs, such as assembly formation, the kinetics of oligomer formation, interactions with various membranes/membrane receptors, the origin of toxicity, and oligomer-specific detection methods. Recently, the discovery of rationally designed antibodies has opened a gateway for using synthesized peptides as a grafting component in the complementarity determining region (CDR) of antibodies. Thus, the Aβ sequence motif or the complementary peptide sequence in the opposite strand of the β-sheet (extracted from the Protein Data Bank: PDB) helps design oligomer-specific inhibitors. The microscopic event responsible for oligomer formation can be targeted, and thus prevention of the overall macroscopic behaviour of the aggregation or the associated toxicity can be achieved. We have carefully reviewed the oligomer formation kinetics and associated parameters. Besides, we have depicted a thorough understanding of how the synthesized peptide inhibitors can impede the early aggregates (oligomers), mature fibrils, monomers, or a mixture of the species. The oligomer-specific inhibitors (peptides or peptide fragments) lack in-depth chemical kinetics and optimization control-based screening. In the present review, we have proposed a hypothesis for effectively screening oligomer-specific inhibitors using the chemical kinetics (determining the kinetic parameters) and optimization control strategy (cost-dependent analysis). Further, it may be possible to implement the structure-kinetic-activity-relationship (SKAR) strategy instead of structure-activity-relationship (SAR) to improve the inhibitor's activity. The controlled optimization of the kinetic parameters and dose usage will be beneficial for narrowing the search window for the inhibitors.

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study

Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer's Pathogenesis

Structural biology of cell surface receptors implicated in Alzheimer’s disease

Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer's disease therapy

An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug Development

Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns

Recent Developments in the Chemical Biology of Amyloid-Β Oligomer Targeting

A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease

Aβ-oligomers: A potential therapeutic target for Alzheimer's disease

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

Molecular Therapeutics in Development to Treat Alzheimer's Disease

Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches

Recent Studies On Mechanisms Of New Drug Candidates For Alzheimer'S Disease Interacting With Amyloid-Beta Protofibrils Using Molecular Dynamics Simulations

Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments

An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects